<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; PTIE</title>
	<atom:link href="http://www.stockbloghub.com/tag/ptie/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Wed, 23 May 2012 20:22:08 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(PFE) Pfizer and Pain Therapeutics Get Bad News for Remoxy</title>
		<link>http://www.stockbloghub.com/2011/06/27/pfe-pfizer-and-pain-therapeutics-get-bad-news-for-remoxy/77578</link>
		<comments>http://www.stockbloghub.com/2011/06/27/pfe-pfizer-and-pain-therapeutics-get-bad-news-for-remoxy/77578#comments</comments>
		<pubDate>Mon, 27 Jun 2011 18:48:24 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[DRRX]]></category>
		<category><![CDATA[Durect Corporation]]></category>
		<category><![CDATA[Pain Therapeutics Inc.]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PTIE]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77578</guid>
		<description><![CDATA[The US Food and Drug Administration recently dealt a blow to Pfizer (PFE) and Pain Therapeutics, Inc. (PTIE) by issuing a second complete response letter (CRL) for their opioid candidate, Remoxy. Remoxy became a part of Pfizer’s pipeline following its acquisition of King Pharmaceuticals earlier this year. Remoxy has been developed, using Durect Corporation’s (DRRX) ORADUR technology, for moderate to severe pain that requires continuous, around-the-clock opioid treatment for an extended period of time. The CRL is a major setback for Pain Therapeutics and Durect Corp. While Pain Therapeutics’ shares dropped more than 40% on the news, Durect’s shares were down 31%. Second CRL for Remoxy Remoxy’s regulatory path has not been smooth with the candidate receiving a second CRL from the FDA. King Pharma had initially submitted the Remoxy ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/27/pfe-pfizer-and-pain-therapeutics-get-bad-news-for-remoxy/77578/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PFE) Pfizer and Acura Pharmaceuticals Win FDA Approval for Oxecta</title>
		<link>http://www.stockbloghub.com/2011/06/23/pfe-pfizer-and-acura-pharmaceuticals-win-fda-approval-for-oxecta/77271</link>
		<comments>http://www.stockbloghub.com/2011/06/23/pfe-pfizer-and-acura-pharmaceuticals-win-fda-approval-for-oxecta/77271#comments</comments>
		<pubDate>Thu, 23 Jun 2011 20:12:32 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACUR]]></category>
		<category><![CDATA[Acura Pharmaceuticals Inc.]]></category>
		<category><![CDATA[DRRX]]></category>
		<category><![CDATA[Durect Corporation]]></category>
		<category><![CDATA[Ingersoll-Rand Company Limited]]></category>
		<category><![CDATA[IR]]></category>
		<category><![CDATA[Pain Therapeutics Inc.]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PTIE]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77271</guid>
		<description><![CDATA[Pfizer Inc. (PFE) and partner Acura Pharmaceuticals Inc. (ACUR) recently received US Food and Drug Administration (FDA) approval for their pain treatment, Oxecta (oxycodone). Oxecta (formerly known as Acurox) gained approval for the management of acute and chronic moderate to severe pain where the use of an opioid analgesic is appropriate. Oxecta became a part of Pfizer’s portfolio following its acquisition of King Pharma earlier this year. Oxecta has been developed under an agreement for the licensing, development, and commercialization of immediate release (IR) pain medicines utilizing Acura&#8217;s Aversion (abuse-deterrent) technology. The abuse-deterrent technology has been designed to discourage opioid abuse and misuse through common ways of tampering. Oxecta’s approval triggers a $20 million milestone payment to Acura from Pfizer. Remoxy Action Date Round the Corner Pfizer has another important ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/23/pfe-pfizer-and-acura-pharmaceuticals-win-fda-approval-for-oxecta/77271/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PFE) Pfizer Extends King Pharmaceuticals Stock Tender Offer</title>
		<link>http://www.stockbloghub.com/2011/01/24/pfe-pfizer-extends-king-pharmaceuticals-stock-tender-offer/65660</link>
		<comments>http://www.stockbloghub.com/2011/01/24/pfe-pfizer-extends-king-pharmaceuticals-stock-tender-offer/65660#comments</comments>
		<pubDate>Tue, 25 Jan 2011 02:49:16 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACUR]]></category>
		<category><![CDATA[Acura Pharmaceuticals Inc.]]></category>
		<category><![CDATA[DRRX]]></category>
		<category><![CDATA[Durect Corporation]]></category>
		<category><![CDATA[Ingersoll-Rand Company Limited]]></category>
		<category><![CDATA[IR]]></category>
		<category><![CDATA[KG]]></category>
		<category><![CDATA[King Pharmaceuticals Inc.]]></category>
		<category><![CDATA[Pain Therapeutics Inc.]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PTIE]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=65660</guid>
		<description><![CDATA[Pfizer Inc. (PFE) recently announced that it has extended the expiration date of its tender offer for all outstanding shares of King Pharmaceuticals, Inc. (KG) by 7 days. The tender offer is now set to expire on January 28, 2011. As of January 20, 2011, about 46.6% of King Pharma’s outstanding shares were validly tendered. Acquisition Deal Announced in October 2010 Pfizer had initially announced its intention to acquire King Pharma on October 12, 2010 for $14.25 per share. The offer price represents a 40% premium to King Pharma’s closing price on Oct 11, 2010. At the time of announcing the acquisition, Pfizer had said that it expects the deal to boost its 2011 and 2012 earnings by 2 cents annually and 2013 – 2015 earnings by 3-4 cents annually. ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/01/24/pfe-pfizer-extends-king-pharmaceuticals-stock-tender-offer/65660/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(KR) King Pharmaceuticals Moves Pain Candidate</title>
		<link>http://www.stockbloghub.com/2010/04/08/kr-king-pharmaceuticals-moves-pain-candidate/33263</link>
		<comments>http://www.stockbloghub.com/2010/04/08/kr-king-pharmaceuticals-moves-pain-candidate/33263#comments</comments>
		<pubDate>Thu, 08 Apr 2010 23:39:01 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Grocery Stores]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[ACUR]]></category>
		<category><![CDATA[Acura Pharmaceuticals Inc.]]></category>
		<category><![CDATA[DRRX]]></category>
		<category><![CDATA[Durect Corporation]]></category>
		<category><![CDATA[KR]]></category>
		<category><![CDATA[Kroger Company]]></category>
		<category><![CDATA[Pain Therapeutics Inc.]]></category>
		<category><![CDATA[PTIE]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=33263</guid>
		<description><![CDATA[King Pharmaceuticals (KR) recently moved pain candidate, Eladur, which has been in-licensed from Durect Corporation (DRRX) into a phase IIb study. Eladur, a transdermal drug patch, is intended to provide continuous delivery of bupivacaine for up to 3 days from a single application, as compared to a wearing time limited to 12 hours with currently available lidocaine patches. The candidate has been developed using Durect’s proprietary TRANSDUR transdermal technology. The phase IIb 12-week, randomized, double-blind, placebo-controlled trial will study the efficacy and safety of Eladur in patients suffering from chronic low back pain. About 260 patients will participate in this study. Eladur became a part of King’s pipeline portfolio following its December 2008 acquisition of Alpharma. In addition to Eladur, King has several pain candidates in its pipeline including Remoxy ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/08/kr-king-pharmaceuticals-moves-pain-candidate/33263/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PTIE) Pain Therapeutics Sees Encouraging Data on PTI-188</title>
		<link>http://www.stockbloghub.com/2010/03/29/ptie-pain-therapeutics-sees-encouraging-data-on-pti-188/31687</link>
		<comments>http://www.stockbloghub.com/2010/03/29/ptie-pain-therapeutics-sees-encouraging-data-on-pti-188/31687#comments</comments>
		<pubDate>Mon, 29 Mar 2010 21:28:37 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[KG]]></category>
		<category><![CDATA[King Pharmaceuticals Inc.]]></category>
		<category><![CDATA[Pain Therapeutics Inc.]]></category>
		<category><![CDATA[PTIE]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=31687</guid>
		<description><![CDATA[Pain Therapeutics, Inc. (PTIE) recently presented encouraging data on its metastatic melanoma candidate, PTI-188. The company said that the administration of a single dose of PTI-188, a radio-labeled monoclonal antibody, resulted in the stabilization or decrease in the size of a number of melanoma tumors. In one of the phase I studies, about 70% of the patients showed stable disease in target lesions at the end of six weeks. The second phase I study showed that about 40% of the patients showed stable disease at week fourteen. PTI-188 was well-tolerated at all doses. Preliminary analysis showed that the median overall survival time based on data from both the studies was 13 months. This represents an improvement over the current median survival time of 9 months in metastatic melanoma patients. The ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/29/ptie-pain-therapeutics-sees-encouraging-data-on-pti-188/31687/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(KG) King Pharmaceuticals Misses Earnings Expectations by a Penny</title>
		<link>http://www.stockbloghub.com/2010/02/28/kg-king-pharmaceuticals-misses-earnings-expectations-by-a-penny/29115</link>
		<comments>http://www.stockbloghub.com/2010/02/28/kg-king-pharmaceuticals-misses-earnings-expectations-by-a-penny/29115#comments</comments>
		<pubDate>Mon, 01 Mar 2010 04:15:34 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[KG]]></category>
		<category><![CDATA[King Pharmaceuticals Inc.]]></category>
		<category><![CDATA[Pain Therapeutics Inc.]]></category>
		<category><![CDATA[PTIE]]></category>
		<category><![CDATA[ZGEN]]></category>
		<category><![CDATA[ZymoGenetics Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=29115</guid>
		<description><![CDATA[King Pharmaceuticals, Inc. (KG) reported fourth-quarter earnings of 23 cents per share, a penny below the Zacks Consensus Estimate. Despite fourth quarter revenues increasing 26.1% from the year-ago period, earnings declined 20.6% from the year-ago quarter, mainly due to higher operating expenses. Full-year earnings, which came in a couple of cents above the Zacks Consensus Estimate at $1.10, declined 28.6% from the year-ago period. Meanwhile, full-year revenues increased 14% to $1.78 billion. Fourth-Quarter Performance Fourth-quarter revenues came in at $439.1 million. King&#8217;s branded pharmaceuticals segment remained flat with revenues coming in at $277 million. While Avinza revenues remained flat, both Skelaxin and Thrombin-JMI sales continued to decline on a year-over-year basis. Thrombin-JMI sales came in at $44 million, down 22.8%. We expect Thrombin-JMI sales to continue declining due to the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/02/28/kg-king-pharmaceuticals-misses-earnings-expectations-by-a-penny/29115/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PTIE) Eleven stocks to watch: February 22, 2010</title>
		<link>http://www.stockbloghub.com/2010/02/23/ptie-eleven-stocks-to-watch-february-22-2010/28476</link>
		<comments>http://www.stockbloghub.com/2010/02/23/ptie-eleven-stocks-to-watch-february-22-2010/28476#comments</comments>
		<pubDate>Wed, 24 Feb 2010 03:55:13 +0000</pubDate>
		<dc:creator>Shawn</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[DTS Inc.]]></category>
		<category><![CDATA[DTSI]]></category>
		<category><![CDATA[ELGX]]></category>
		<category><![CDATA[Endologix Inc]]></category>
		<category><![CDATA[Integrated Silicon Solution Inc]]></category>
		<category><![CDATA[ISSI]]></category>
		<category><![CDATA[LANC]]></category>
		<category><![CDATA[Lancaster Colony Corporation]]></category>
		<category><![CDATA[MEND]]></category>
		<category><![CDATA[Micrus Endovascular Corporation]]></category>
		<category><![CDATA[Pain Therapeutics Inc.]]></category>
		<category><![CDATA[PBIB]]></category>
		<category><![CDATA[Perrigo Company]]></category>
		<category><![CDATA[Porter Bancorp Inc.]]></category>
		<category><![CDATA[PRGO]]></category>
		<category><![CDATA[PTIE]]></category>
		<category><![CDATA[Sara Lee Corporation]]></category>
		<category><![CDATA[SLE]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=28476</guid>
		<description><![CDATA[Each weekend I use Barchart to screen for a list of stocks that I think may be of interest to my readers in the coming week. I am not recommending these stocks, I just want to share with you a screening process and it&#8217;s up to you to do further research and see if there is a place in your portfolio for these issues. I start with the list of stocks hitting new highs and lows for the last 20 days and sort for frequency. I then take the top 10 from each list that have hit new milestones in at least 50% of the last 20 sessions. That list of the 10 top gainers and 10 top losers is where I start. I put them all in a test ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/02/23/ptie-eleven-stocks-to-watch-february-22-2010/28476/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PTIE) Financial Tides Positions &#8211; The Long and Short of it &#8211; February 16,2010</title>
		<link>http://www.stockbloghub.com/2010/02/15/ptie-financial-tides-positions-the-long-and-short-of-it-february-162010/28061</link>
		<comments>http://www.stockbloghub.com/2010/02/15/ptie-financial-tides-positions-the-long-and-short-of-it-february-162010/28061#comments</comments>
		<pubDate>Mon, 15 Feb 2010 23:04:34 +0000</pubDate>
		<dc:creator>Shawn</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[MEND]]></category>
		<category><![CDATA[Micrus Endovascular Corporation]]></category>
		<category><![CDATA[Pain Therapeutics Inc.]]></category>
		<category><![CDATA[Parkway Properties Inc.]]></category>
		<category><![CDATA[PKY]]></category>
		<category><![CDATA[PTIE]]></category>
		<category><![CDATA[Regeneron Pharmaceuticals Inc]]></category>
		<category><![CDATA[REGN]]></category>
		<category><![CDATA[SGB]]></category>
		<category><![CDATA[Southwest Georgia Financial Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=28061</guid>
		<description><![CDATA[Each day I go on Barchart and sort the new high and new low list for frequency. I then take the top 10 highs and the top 10 lows and do additional screening. I&#8217;ll list here those that pass and might be good additions to your portfolio. Use this list as a starting point and then investigate each stock to see if it has a place in your portfolio. Buy Long Stocks: (PTIE) &#8211; Pain Therapeutics &#8211; 100% buy &#8211; 13 of 20 days of price appreciation and monthly return 16.17% Pain Therapeutics is developing a new generation of opioid painkillers.Opioids are drugs derived from the poppy plant. The company uses technology to reformulate opioid drugs, such as morphine, into new painkillers with improved clinical benefits. The company has four ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/02/15/ptie-financial-tides-positions-the-long-and-short-of-it-february-162010/28061/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>($KG) King Pharmaceuticals Beats Consensus, but Earnings Down</title>
		<link>http://www.stockbloghub.com/2009/11/07/kg-king-pharmaceuticals-beats-consensus-but-earnings-down/19827</link>
		<comments>http://www.stockbloghub.com/2009/11/07/kg-king-pharmaceuticals-beats-consensus-but-earnings-down/19827#comments</comments>
		<pubDate>Sun, 08 Nov 2009 00:35:35 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[KG]]></category>
		<category><![CDATA[King Pharmaceuticals Inc.]]></category>
		<category><![CDATA[Pain Therapeutics Inc.]]></category>
		<category><![CDATA[PTIE]]></category>
		<category><![CDATA[ZGEN]]></category>
		<category><![CDATA[ZymoGenetics Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=19827</guid>
		<description><![CDATA[King Pharmaceuticals, Inc. (KG) reported third quarter earnings of 29 cents per share, beating the Zacks Consensus Estimate by 2 cents. Despite revenues increasing 19.3% from the year-ago period, earnings declined 25.6% from the year-ago quarter mainly due to higher operating expenses. Total revenues came in at $463.3 million. The primary growth drivers were the Animal Health business, which came as a part of the Alpharma acquisition and an increase in sales of auto-injectors in the Meridian business. King’s branded pharmaceuticals segment posted revenues of $283 million, down 6.3% from the prior-year period. While generic versions of Altace continued to impact the top-line, both Skelaxin and Thrombin-JMI sales continued to decline on a year-over-year basis. Thrombin-JMI sales came in at $43 million, down 35.8%. We expect Thrombin-JMI sales to continue ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/07/kg-king-pharmaceuticals-beats-consensus-but-earnings-down/19827/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(KG) King Pharmaceuticals Launches Embeda for Around-The-Clock Pain Relief</title>
		<link>http://www.stockbloghub.com/2009/09/24/kg-king-pharmaceuticals-launches-embeda-for-around-the-clock-pain-relief/16013</link>
		<comments>http://www.stockbloghub.com/2009/09/24/kg-king-pharmaceuticals-launches-embeda-for-around-the-clock-pain-relief/16013#comments</comments>
		<pubDate>Thu, 24 Sep 2009 19:39:12 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Featured]]></category>
		<category><![CDATA[ACUR]]></category>
		<category><![CDATA[Acura Pharmaceuticals Inc.]]></category>
		<category><![CDATA[DRRX]]></category>
		<category><![CDATA[Durect Corp.]]></category>
		<category><![CDATA[KG]]></category>
		<category><![CDATA[King Pharmaceuticals Inc.]]></category>
		<category><![CDATA[Pain Therapeutics Inc.]]></category>
		<category><![CDATA[PTIE]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=16013</guid>
		<description><![CDATA[Earlier this week, King Pharmaceuticals, Inc. (KG) announced the launch of Embeda, which recently received U.S. Food and Drug Administration (FDA) approval for the management of moderate to severe pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time. Embeda, which is the first FDA-approved long-acting opioid designed to reduce drug liking and euphoria when tampered with by crushing or chewing, will be available in six dosage strengths. As per the requirement of the FDA, the company has also implemented a Risk Evaluation and Mitigation Strategy (REMS) under which patients and providers will be informed about the potential for abuse, misuse, overdose, and addiction of Embeda and about the safe use of the opioid. The approval and launch of Embeda is a significant milestone for ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/24/kg-king-pharmaceuticals-launches-embeda-for-around-the-clock-pain-relief/16013/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

